Loading...
15 casirivimab/imdevimab COVID-19 controlled studies, 9 RCTs
https://c19regn.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Regeneron (RCT) 38%
0.62 [0.30-1.28]
recov. time
92 (n)
91 (n)
Improvement, RR [CI] Treatment Control Regeneron (RCT) 54%
0.46 [0.20-1.08]
recov. time
92 (n)
91 (n)
Regeneron (RCT) 71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Regeneron (RCT) 70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Regeneron (RCT) 29%
0.71 [0.60-0.85]
recov. time
1,355 (n)
1,341 (n)
Regeneron (RCT) 29%
0.71 [0.60-0.85]
recov. time
736 (n)
748 (n)
Weinreich (RCT) 50%
0.50 [0.09-2.72]
death
2/2,091
4/2,089
Weinreich (RCT) 67%
0.33 [0.03-3.17]
death
1/1,355
3/1,341
Weinreich (RCT) -2%
1.02 [0.06-16.2]
death
1/736
1/748
Weinreich (RCT) 71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Weinreich (RCT) 70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Weinreich (RCT) 29%
0.71 [0.58-0.87]
recov. time
1,355 (n)
1,341 (n)
Weinreich (RCT) 29%
0.71 [0.58-0.87]
recov. time
736 (n)
748 (n)
Webb 98%
0.02 [0.00-0.27]
death
0/115
57/5,536
Webb 91%
0.09 [0.01-0.63]
hosp.
1/115
538/5,536
Cooper 77%
0.23 [0.03-1.65]
death
1/1,148
33/8,534
Cooper 48%
0.52 [0.23-1.20]
ICU
6/1,148
85/8,534
Cooper 52%
0.48 [0.35-0.64]
hosp.
45/1,148
703/8,534
Kakinoki 58%
0.42 [0.17-0.92]
progression
13/55
22/53
Komagamine 77%
0.23 [0.01-4.63]
ventilation
0/53
2/75
Komagamine 92%
0.08 [0.00-1.32]
ICU
0/53
7/75
Komagamine 68%
0.32 [0.13-0.68]
progression
8/53
33/75
Komagamine 29%
0.71 [0.58-0.87]
hosp. time
53 (n)
75 (n)
Suzuki (PSM) -200%
3.00 [0.12-73.3]
death
1/222
0/222
Suzuki 60%
0.40 [0.05-3.45]
death
1/314
5/635
Suzuki (PSM) 45%
0.55 [0.31-0.96]
progression
17/222
31/222
Suzuki 50%
0.50 [0.31-0.80]
progression
34/314
70/365
O'Brien (DB RCT) 85%
0.15 [0.01-2.78]
hosp.
0/100
3/104
O'Brien (DB RCT) 92%
0.08 [0.00-1.37]
hosp./ER
0/100
6/104
O'Brien (DB RCT) 33%
0.67 [0.43-0.98]
symp. case
29/100
44/104
O'Brien (DB RCT) 40%
0.60 [0.45-0.81]
viral load
100 (n)
104 (n)
Horby (RCT) 6%
0.94 [0.86-1.03]
death
944/4,839
1,026/4,946
Horby (RCT) 0%
1.00 [0.89-1.13]
ventilation
479/4,556
487/4,642
Horby (RCT) 20%
0.80 [0.70-0.91]
death
396/1,633
451/1,520
Horby (RCT) 12%
0.88 [0.73-1.06]
ventilation
189/1,599
200/1,484
Somersan.. (DB RCT) 36%
0.64 [0.44-0.93]
death
59/804
45/393
Somersan.. (DB RCT) 56%
0.44 [0.26-0.76]
death
24/360
24/160
Somersan.. (DB RCT) 21%
0.79 [0.44-1.40]
death
26/369
18/201
Somersan.. (DB RCT) 31%
0.69 [0.50-0.95]
death/int.
82/804
58/393
Somersan.. (DB RCT) 29%
0.71 [0.53-0.96]
no disch.
92/804
63/393
McCreary (PSM) 93%
0.07 [0.01-0.51]
death
1/652
29/1,304
McCreary (PSM) 56%
0.44 [0.28-0.68]
death/hosp.
22/652
101/1,304
McCreary (PSM) 48%
0.52 [0.33-0.82]
hosp.
22/652
85/1,304
McCreary (PSM) 40%
0.60 [0.43-0.85]
hosp./ER
40/652
133/1,304
Regeneron (RCT) 94%
0.06 [0.00-1.10]
symp. case
0/186
8/223
Regeneron (RCT) 48%
0.52 [0.25-1.07]
cases
10/186
23/223
Regeneron (DB RCT) 92%
0.08 [0.00-1.36]
hosp.
0/841
6/842
Regeneron (DB RCT) 81%
0.19 [0.12-0.30]
cases
20/841
108/842
Regeneron (DB RCT) 82%
0.18 [0.08-0.41]
cases
7/841
38/842
Regeneron (DB RCT) 89%
0.11 [0.01-2.06]
hosp./ER
0/753
4/752
Regeneron (DB RCT) 81%
0.19 [0.10-0.35]
symp. case
11/753
59/752
Regeneron (DB RCT) 62%
0.38 [0.23-0.61]
recov. time
753 (n)
752 (n)
Regeneron (DB RCT) 69%
0.31 [0.17-0.55]
viral time
753 (n)
752 (n)
Isa (DB RCT) 93%
0.07 [0.01-0.28]
symp. case
3/729
13/240
Isa (DB RCT) 93%
0.07 [0.01-0.28]
cases
0/729
10/240
casirivimab/imdevimab COVID-19 outcomes c19regn.com Jan 22, 2022
Favors casiri/imdevimab
Favors control
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
WCH
and
FLCCC provide
treatment protocols.
Submit
